Table 5 Clinical characteristics according to the expression of ROCK1
From: Clinical significance of mTOR, ZEB1, ROCK1 expression in lung tissues of pulmonary fibrosis patients
|  | ROCK1 negative,intermediate(n = 16) | ROCK1 strong(n = 14) | p value |
|---|---|---|---|
Age, years, median (range) | 63 (39-74) | 55 (38-72) | 0.110 |
Male sex | 7 (43.8) | 7 (50.0) | 1.000 |
Ever smoker | 6 (37.5) | 5 (35.7) | 1.000 |
FVC, % | 73.6 ± 13.6 | 74.5 ± 17.9 | 0.871 |
DLCO, % | 58.4 ± 21.7 | 68.8 ± 33.2 | 0.332 |
PaO2, mmHg | 92.8 ± 12.3 | 91.1 ± 19.9 | 0.784 |
BAL Neutrophil, % | 32.4 ± 26.8 | 14.7 ± 14.3 | 0.129 |
BAL Lymphocyte, % | 18.8 ± 12.5 | 16.3 ± 7.6 | 0.646 |
Radiologic honeycombing score | 1.7 ± 2.7 | 2.4 ± 2.6 | 0.496 |
Histologic fibrosis score | 10.1 ± 8.7 | 15.0 ± 8.1 | 0.123 |
Δ FVC, mL | - 20 ± 190 | - 45 ± 401 | 0.856 |
Δ DLCO, mL/mmHg/min | - 0.05 ± 1.72 | - 0.59 ± 2.33 | 0.547 |
Δ FVC, % | 0.4 ± 6.3 | 0.8 ± 17.8 | 0.936 |
Δ DLCO, % | 1.0 ± 10.3 | -1.9 ± 11.9 | 0.530 |
Survivors | 12 (75.0) | 12 (85.7) | 0.657 |
mTOR | 3.1 ± 2.9 | 5.4 ± 2.7 | 0.033 |
ZEB1 | 2.9 ± 2.9 | 3.4 ± 2.3 | 0.361 |